DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

Valued at a market cap of $27.5 billion, San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that ...

On the other hand, DexCom is a pure-play CGM company whose target market consists mainly of people with Type 1 and Type 2 ...

If you are wondering whether DexCom stock still offers value after a choppy few years, this article walks through what the ...

DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...

Shares of DexCom Inc. DXCM advanced 3.47% to $71.25 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX remaining mostly unchanged at 7, ...

Shares of diabetes management equipment provider DexCom (NASDAQ: DXCM) had tumbled 17% by 11:15 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The culprit was the ...

DexCom (NASDAQ:DXCM) stock experienced a significant 16% surge on Friday following its Q1 earnings release and a share buyback announcement. The company’s first-quarter sales reached $1.04 billion, ...

DexCom (DXCM) faces GLP-1 disruption as it targets non-insulin Type 2 CGM growth. Read here for a detailed invesment analysis ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...